UMeWorld Announces Strategic Expansion in the U.S. and Forecasts Significant Revenue Growth
May 16, 2024 08:00 ET
|
UMeWorld Limited
HONG KONG, May 16, 2024 (GLOBE NEWSWIRE) -- UMeWorld Limited (OTCPK: UMEWF) is pleased to announce a strategic plan for expansion in the United States. Having secured proprietary enzymatic...
Reddit's Analysis on the Efficacy of FDA Approved Leading Weight Loss Drugs, Q4 2023 - Q2 2024: Focus on Semaglutide, Naltrexone-bupropion, Tirzepatide, Phentermine-topiramate, Liraglutide, Hydrogel
May 14, 2024 10:43 ET
|
Research and Markets
Dublin, May 14, 2024 (GLOBE NEWSWIRE) -- The "Reddit's Analysis on the Efficacy of Leading Weight Loss Drugs" report has been added to ResearchAndMarkets.com's offering.This comprehensive...
Will your health insurance cover weight-loss medications? It depends on several factors, including where you live
May 08, 2024 11:23 ET
|
medicareresources.org
Minneapolis, MN, May 08, 2024 (GLOBE NEWSWIRE) -- Interest in medications prescribed for weight loss is skyrocketing, sparking consumer questions about whether health insurance covers these...
Weight Loss/Weight Management (Obesity) Pipeline Insight, 2024: Drugs Under Development, Unmet Needs, Key Players, Collaborations, Licensing Agreement and Financing Details
May 08, 2024 05:39 ET
|
Research and Markets
Dublin, May 08, 2024 (GLOBE NEWSWIRE) -- The "Weight Loss/Weight Management (Obesity) - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report...
European $45 Billion Weight Loss Management Market Outlook to 2029: Rise of Personalised Nutrition and Wellness, Data-Driven Personalisation, Increasing Obesity Rates
May 07, 2024 05:07 ET
|
Research and Markets
Dublin, May 07, 2024 (GLOBE NEWSWIRE) -- The "Europe Weight Loss Management Market Outlook, 2029" report has been added to ResearchAndMarkets.com's offering.Europe Weight Loss and Weight Management...
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
May 02, 2024 08:30 ET
|
Elevai Labs Inc.
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
May 01, 2024 09:00 ET
|
Elevai Labs Inc.
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
UMeWorld Limited Updates Investors on Acquisition, Uplist and Relocation
April 30, 2024 08:00 ET
|
UMeWorld Limited
MIAMI, April 30, 2024 (GLOBE NEWSWIRE) -- UMeWorld Limited (OTC: UMEWF) is thankful to have the opportunity to update existing and future shareholders of the company operations and 2024 strategy...
Weight Loss Drugs Market Trends Analysis 2018-2023 and Opportunities Forecast 2024-2033 Featuring Pfizer, Roche, Merck & Co, AbbVie, and Novartis
April 24, 2024 04:12 ET
|
Research and Markets
Dublin, April 24, 2024 (GLOBE NEWSWIRE) -- The "Weight Loss Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The weight loss drugs market size has...
Enhanced Inventory Management Solutions to Meet Rising E-Commerce Demand
April 23, 2024 08:05 ET
|
LadyBug Resource Group, Inc.
Enhanced Inventory Management Solutions to Meet Rising E-Commerce Demand